CBD, Nutrient Metabolism and Energy Intake

NCT ID: NCT05618756

Last Updated: 2025-02-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-30

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CBD may affect metabolic control and energy intake. However, there is currently little data regarding these specific outcomes in humans. Therefore, this study will investigate whether a single 300 mg dose of CBD can improve metabolic control following a meal and/or reduce energy intake at a subsequent meal. Healthy, adult volunteers will complete two conditions in a crossover design, comparing outcomes following both CBD and placebo supplementation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glucose Metabolism Disorders (Including Diabetes Mellitus) Lipid Metabolism Disorders Appetitive Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cannabidiol

300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.

Group Type EXPERIMENTAL

Acute oral CBD supplementation

Intervention Type DIETARY_SUPPLEMENT

1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.

Placebo

1 ml hemp oil. Provided orally in gelatin capsules.

Group Type PLACEBO_COMPARATOR

Acute oral placebo supplementation

Intervention Type DIETARY_SUPPLEMENT

1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acute oral CBD supplementation

1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.

Intervention Type DIETARY_SUPPLEMENT

Acute oral placebo supplementation

1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Self-report as healthy, male or female, aged 18-50, body mass index ≥18.5 and \<30.0

Exclusion Criteria

* Currently engage in \>10 hours moderate or vigorous intensity physical activity per week
* Have consumed CBD or cannabis at all within the past two months
* Have used CBD or cannabis regularly (\>2x in a week) within the past four months
* Are suffering from any clinically significant illness
* Have regularly used tobacco within the previous 6 months (\> 2/week)
* Currently use any prescription or over-the-counter medications (except for hormonal contraception and simple painkillers)
* Have given a standard blood donation within 30 days of screening
* Are currently pregnant or lactating
* Are allergic/intolerant to any ingredients in food items provided during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Loughborough University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lewis James

Senior Lecturer in Nutrition

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loughborough University

Loughborough, Leicestershire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5553

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Energy Balance Weight Regulation Study
NCT00619008 COMPLETED PHASE2
Fat Burning After a Meal
NCT02211599 COMPLETED NA